“We are excited for NAMSA to serve as an exclusive partner to help patients access joimax®’ endoscopic technologies,” stated joimax® General Manager Maximilian Ries. “We’re optimistic that with NAMSA’s assistance, and the nearly 5,000 clinical papers on endoscopic spine surgery, we will continue to expand coverage of this important, minimally-invasive technology.”
For details, visit www.joimax.com.
Founded in Karlsruhe, Germany in 2001, joimax® is the leading developer and marketer of complete systems for full-endoscopic and minimally-invasive spinal surgery. With the Endoscopic Surgical Systems TESSYS® (transforaminal), iLESSYS® (interlaminar) and CESSYS® (cervical) for decompression procedures, MultiZYTE® for facet and sacroiliac joint pain treatment, EndoLIF® and Percusys® for minimally-invasive endoscopically assisted stabilizations, established systems are provided, addressing a whole range of indications. In procedures for herniated disc, stenosis, pain therapy or spinal stabilization treatment, surgeons utilize joimax® technologies to operate through small incisions under local or full anesthesia, via tissue and muscle-sparing corridors and through natural openings in the spinal canal, e.g. the intervertebral foramen, the so-called “Kambin triangle”.
joimax®, the German-based market leader in technologies and training methods for full-endoscopic and minimally-invasive spinal surgery, is pleased to announce a new strategic partnership with NAMSA, the only full continuum Contract Research Organization (CRO) in the world focused exclusively on medical devices. Recognized as a leader in reimbursement strategies, with years of experience in collaborating with public and private payors, NAMSA will assist joimax®’ customers with reimbursement support services, including prior authorization and appeals support, across the United States.
Since the creation of American Medical Association medical procedural code CPT® 62380, Endoscopic Decompression of Neural Elements and/or Excision of Herniated Intervertebral Discs, in 2017, utilization of endoscopic spinal procedures has grown.
Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world’s only 100% medical device-focused, full continuum Contract Research Organization (CRO). Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients’ products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services; NAMSA is the industry’s premier, trusted partner for successful development and commercialization outcomes. http://www.namsa.com
View source version on businesswire.com:https://www.businesswire.com/news/home/20210721005247/en/ CONTACT: Press Contact Germany:
joimax® GmbH Nicole Read
Nicole.Read@joimax.com 0049-721-25514-0Press Contact USA:
joimax® Inc. Tony Troncale